Emily Symington

2.0k total citations · 1 hit paper
14 papers, 528 citations indexed

About

Emily Symington is a scholar working on Hematology, Genetics and Surgery. According to data from OpenAlex, Emily Symington has authored 14 papers receiving a total of 528 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Hematology, 4 papers in Genetics and 3 papers in Surgery. Recurrent topics in Emily Symington's work include Hemophilia Treatment and Research (8 papers), Virus-based gene therapy research (3 papers) and CAR-T cell therapy research (2 papers). Emily Symington is often cited by papers focused on Hemophilia Treatment and Research (8 papers), Virus-based gene therapy research (3 papers) and CAR-T cell therapy research (2 papers). Emily Symington collaborates with scholars based in United Kingdom, United States and Australia. Emily Symington's co-authors include Savita Rangarajan, Glenn F. Pierce, John Pasi, Bella Madan, Will Lester, Wing Yen Wong, Michael Laffan, Nina Mitchell, Mingjin Li and Chris B. Russell and has published in prestigious journals such as New England Journal of Medicine, Blood and CHEST Journal.

In The Last Decade

Emily Symington

13 papers receiving 519 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A

2020 327 citations John Pasi, Savita Rangarajan et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Emily Symington

Since Specialization

Citations

This map shows the geographic impact of Emily Symington's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emily Symington with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emily Symington more than expected).

Fields of papers citing papers by Emily Symington

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emily Symington. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emily Symington. The network helps show where Emily Symington may publish in the future.

Co-authorship network of co-authors of Emily Symington

This figure shows the co-authorship network connecting the top 25 collaborators of Emily Symington. A scholar is included among the top collaborators of Emily Symington based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emily Symington. Emily Symington is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Efficacy and safety of valoctocogene roxaparvovec 4 years after gene transfer in GENEr8-1 2025 ·Hämostaseologie ·Andrew D. Leavitt, Johnny Mahlangu, (unknown), Emily Symington, Doris Quon, Adam Giermasz, Gili Kenet, Gillian Lowe, Nigel S. Key, (unknown), Steven W. Pipe, (unknown), (unknown), Robert Klamroth, Jody M. Mason, Hérvè Chambost, Flora Peyvandi, Haiyan Yu, Tara M. Robinson, Margareth C. Ozelo	0
2	Valoctocogene roxaparvovec gene therapy provides durable haemostatic control for up to 7 years for haemophilia A 2024 ·Haemophilia ·Emily Symington, Savita Rangarajan, Will Lester, Bella Madan, Glenn F. Pierce, (unknown), Carolyn M. Millar, (unknown), Mingjin Li, Tara M. Robinson	14
3	Long‐term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post‐treatment 2024 ·Haemophilia ·Emily Symington, Savita Rangarajan, Will Lester, Bella Madan, Glenn F. Pierce, (unknown), Tara M. Robinson, (unknown), Chris B. Russell, Christian Vettermann, Suresh Agarwal, Mingjin Li, Wing Yen Wong, Michael Laffan	17
4	A Case of Thrombotic Microangiopathy and Acute Sarcoidosis 2022 ·CHEST Journal ·Anthony W. Martinelli, William G. Dunn, (unknown), (unknown), Andrew F. Stewart, (unknown), (unknown), S Thiru, Nicholas Torpey, Sanjay Kumar Ojha, Emily Symington, James A. Nathan	2
5	Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A 2021 ·Haemophilia ·John Pasi, Michael Laffan, Savita Rangarajan, Tara M. Robinson, Nina Mitchell, Will Lester, Emily Symington, Bella Madan, Xinqun Yang, Benjamin Kim, Glenn F. Pierce, Wing Yen Wong	70
6	A WITHIN-PATIENT COMPARISON OF EFFICACY AND OUTCOME OF RECOMBINANT FIX AND FIXFC IN HAEMOPHILIA B IN THE UK 2020 ·Haemophilia ·(unknown), M.J. Scott, C. R. M. Hay, Peter W. Collins, Hua Xiang, Susan Shapiro, Pratima Chowdary, Emily Symington, Richard Gooding, (unknown)	2
7	Activity of transgene-produced B-domain–deleted factor VIII in human plasma following AAV5 gene therapy 2020 ·Blood ·S. Rosén, Stefan Tiefenbacher, Mary Robinson, (unknown), Jaydeep K. Srimani, (unknown), Terri Christianson, John Pasi, Savita Rangarajan, Emily Symington, Adam Giermasz, Glenn F. Pierce, Benjamin Kim, Stephen J. Zoog, Christian Vettermann	49
8	A FIRST-IN-HUMAN FOUR-YEAR FOLLOW-UP STUDY OF DURABLE THERAPEUTIC EFFICACY AND SAFETY OF AAV GENE THERAPY WITH VALOCTOCOGENE ROXAPARVOVEC FOR SEVERE HEMOPHILIA A 2020 ·Hematology Transfusion and Cell Therapy ·Margareth C. Ozelo, John Pasi, Savita Rangarajan, Nina Mitchell, Will Lester, Emily Symington, (unknown), Michael Laffan, Chris B. Russell, (unknown), (unknown), Glenn F. Pierce, Wing-Yen Wong	3
9	Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A breakdown → 2020 ·New England Journal of Medicine ·John Pasi, Savita Rangarajan, Nina Mitchell, Will Lester, Emily Symington, Bella Madan, Michael Laffan, Chris B. Russell, Mingjin Li, Glenn F. Pierce, Wing Yen Wong	327
10	A hypercoagulable state leading to venous limb gangrene associated with occult lung adenocarcinoma 2019 ·Clinical Case Reports ·(unknown), Anthony W. Martinelli, Stephen Preston, Emma Gudgin, Emily Symington, Robert C. Rintoul, Adam Peryt, Patrick A. Coughlin, Paul D. Hayes, David Gilligan, Martin Besser	4
11	Characterization of a large cohort of patients with unclassified bleeding disorder; clinical features, management of haemostatic challenges and use of global haemostatic assessment with proposed recommendations for diagnosis and treatment 2019 ·International Journal of Laboratory Hematology ·Stephen MacDonald, (unknown), (unknown), Kate Downes, Martin Besser, Emily Symington, Anne M. Kelly, Will Thomas	25
12	An unusual cause of unilateral adrenal haemorrhage 2017 ·Endocrine Abstracts ·(unknown), Emily Symington, John C. Clark	1
13	Does bleeding affect patient‐reported outcome measures in patients with myelodysplasia or hematologic malignancies: a systematic review 2013 ·Transfusion ·Lise J Estcourt, (unknown), Emily Symington, Anne M. Kelly, Carolyn Dorée, Susan J Brunskill, Liz Glidewell, Simon Stanworth	13
14	Compromise of renal transplant blood flow by an arteriovenous graft 2006 ·Nephrology Dialysis Transplantation ·Emily Symington, Behdad Afzali, Iain MacPhee, Eric S. Chemla	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact